Find out more about us and our portfolio companies

Brings extensive small molecule drug discovery, development, and clinical experience across multiple therapeutic areas.

Will drive application of Outrun’s novel, proprietary X-E3L platform for protein stabiliser discovery to develop a pipeline of high-quality drug candidates targeting E3 ligases.

Continues strong momentum following 2024 emergence from stealth with $10M seed financing.

Cohu, Inc. (NASDAQ: COHU), a global supplier of equipment and services optimizing semiconductor manufacturing yield and productivity, today announced that it has entered into a definitive agreement to acquire Tignis, Inc. (“Tignis”), a provider of artificial intelligence (AI) process control and analytics-based monitoring software.